10-Q · May 4, 2026
Biohaven Ltd. reported its Q1 2026 financial results with a net loss of $130.5 million, a significant improvement from a net loss of $221.7 million in Q1 2025, driven by a reduction in operating expenses primarily due…
Earnings analysis · 10-Q
BHVN earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, segment disclosures, or quantitative MD&A outlook, so revenue, margins, EPS, cash flow, and working-capital trends…
Read full summary
The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, segment disclosures, or quantitative MD&A outlook, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed. Risk factors were unchanged materially from the prior 10-K, while management reported effective disclosure controls as of June 30, 2026. Market-risk exposure appears limited, with a 1.00% interest-rate move estimated to affect investment fair value by approximately $0.2 million.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Foreign-currency exposure immaterial
Management reported that monetary exposures on the condensed consolidated balance sheet were immaterial as of June 30, 2026.
-
Limited interest-rate sensitivity
A 1.00% increase or decrease in interest rates would change the fair value of the investment portfolio by approximately $(0.2) million or $0.2 million, respectively.
-
No recorded investment credit losses
The company stated it had not experienced any credit losses or recorded any allowance for credit losses related to cash, cash equivalents, and short-term debt securities.
-
Disclosure controls effective
The CEO and CFO concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
-
No material control changes
There was no change in internal control over financial reporting during the 3 months ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, those controls.
What to watch
-
Unhedged foreign-currency exposure
The company does not hedge foreign-currency exposure, and its operations include activities in countries outside the U.S.; monetary exposures were described as immaterial as of June 30, 2026.
-
Investment portfolio rate risk
The company does not hedge interest-rate exposure; a 1.00% rate move would change the investment portfolio's fair value by approximately $0.2 million in either direction.
-
No material risk-factor update
Risk factors had not changed materially from the December 31, 2025 Form 10-K filed March 2, 2026; therefore, no material new or updated risk-factor changes were identified.
Management's outlook
The provided 10-Q text contains no quantitative revenue or EPS outlook; numeric guidance is not provided.
Earlier filings 4
10-K · March 2, 2026
Biohaven’s 2025 10‑K describes a strategic refocus (initiated Q4 2025) to prioritize three late‑stage platforms (Kv7 ion channel modulators, MoDE/TRAP extracellular degraders, and a myostatin‑activin program).…
10-Q · May 12, 2025
The 10-Q contains extensive clinical and pipeline updates but does not include period income statement, balance sheet or cash-flow line items in the text provided. Material corporate financing occurred after…
10-Q · August 9, 2024
Biohaven's 10-Q emphasizes an active clinical pipeline with multiple near-term catalysts (several topline readouts and trial initiations expected in H2 2024–H1 2025) and a series of material share-based transactions…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.